-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Margetuximab in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Margetuximab in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Margetuximab in Non-Small Cell Lung Cancer Drug Details: Margetuximab (Margenza)...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Margetuximab in Extrahepatic Bile Duct Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Margetuximab in Extrahepatic Bile Duct Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Margetuximab in Extrahepatic Bile Duct Cancer Drug Details: Margetuximab (Margenza)...
-
Product Insights
NewAirway Management Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies
Airway Management Pipeline Market Report Overview Airway management refers to medical procedures performed for the prevention or alleviation of any obstruction in the airway. Airway management procedures are performed to open a pathway for maintaining or re-storing proper gas exchange between a patient's lungs and the atmosphere. This is accomplished with the use of an infraglottic device (Endotracheal tubes) supraglottic device (Laryngeal mask) or surgical method (Tracheostomy). The devices used for airway management are referred to as airway management devices....
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CDX-585 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CDX-585 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CDX-585 in Solid Tumor Drug Details: CDX-585 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GLR-2007 in Metastatic Brain Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GLR-2007 in Metastatic Brain Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. GLR-2007 in Metastatic Brain Tumor Drug Details: GLR-2007 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GLR-2007 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GLR-2007 in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. GLR-2007 in Non-Small Cell Lung Cancer Drug Details: GLR-2007 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GLR-2007 in Recurrent Glioblastoma Multiforme (GBM)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GLR-2007 in Recurrent Glioblastoma Multiforme (GBM) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. GLR-2007 in Recurrent Glioblastoma Multiforme (GBM) Drug Details: GLR-2007 is...
-
Product Insights
Persistent Corneal Epithelial Defects – Drugs In Development, 2023
Global Markets Direct’s, ‘Persistent Corneal Epithelial Defects - Drugs In Development, 2023’, provides an overview of the Persistent Corneal Epithelial Defects pipeline landscape. The report provides comprehensive information on the therapeutics under development for Persistent Corneal Epithelial Defects, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Germ Cell Tumors – Drugs In Development, 2023
Global Markets Direct’s, ‘Germ Cell Tumors - Drugs In Development, 2023’, provides an overview of the Germ Cell Tumors pipeline landscape. The report provides comprehensive information on the therapeutics under development for Germ Cell Tumors, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ensartinib Hydrochloride in Pediatric Diffuse Intrinsic Pontine Glioma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Ensartinib Hydrochloride in Pediatric Diffuse Intrinsic Pontine Glioma Drug Details: Ensartinib hydrochloride (Bemena) is an...